Regeneron and Sanofi Present Dupixent Trial Results
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the REMODEL Phase 4 trial demonstrating that Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility and disease-related structural changes compared to placebo in adults with eosinophilic esophagitis at week 24. "Dupixent showed a potential to modify the course of eosinophilic esophagitis - by improving esophageal size at just 6 months - the magnitude of this improvement corresponded to the benefit that could be seen from an esophageal dilation procedure," said Evan Dellon, lead author of the study. At week 24, Dupixent showed a 1.28 mm improvement in esophageal distensibility plateau from baseline compared to -0.01 mm for placebo. Additionally, 59% of patients achieved peak esophageal intraepithelial counts of less than or equal to 6 eosinophils per high-power field compared to 4% for placebo. The results reinforce the previously established ability of Dupixent to address underlying inflammation and symptoms of this disease.
